True Appoints Kate Vanek as General Manager, International
19.4.2022 09:03:00 EEST | Business Wire | Press release
True, the fastest-growing global platform of innovative talent management products and services, announced today it has appointed Kate Vanek as general manager, international. Kate joins True from BlackRock where she held the dual responsibility of CFO of EMEA and COO of global finance.
In her role, Kate will work closely with True’s global leadership to enhance and expand the firm’s international executive search business and broader platform of talent management products and services including Thrive, Synthesis, and AboveBoard. Kate is London-based and will oversee the international business across EMEA and APAC, which today includes True's offices in Amsterdam, Berlin, Dubai, London, Melbourne, Shanghai, Singapore, Stockholm, Sydney and Tel Aviv.
“Kate has a passion for talent management and a dynamic, inspirational leadership style,” said Joe Riggione, True co-founder and co-CEO. “She’s a high-performance operator who combines her personal and business experiences to connect people and complex global organizations. She is an impressive leader with an extraordinary track record, and we are lucky to have her.”
“I’m thrilled to be joining True during this period of expansion, and I’m excited to help propel True’s vision to build the global talent management firm of the future,” Kate commented. “True’s special culture and commitment to investing in its people, combined with their world-class executive search expertise and cutting-edge platform make it a place I couldn’t be more proud to join.”
“Kate's experience in strategic business building prepares her to expand our offerings globally to meet the needs of our clients who rely on True’s talent expertise and platform to help them grow and thrive,” said Brad Stadler, True co-founder and co-CEO.
Kate Vanek, True’s GM, International
Kate’s background has rich diversity of experience in finance, strategy and business operations, M&A, investor relations, DE&I initiatives, and leadership development. She has managed global teams in leadership roles across a range of industries from financial services, data science, consumer behavior measurement to industrials.
ABOUT TRUE
True is a platform of products and services driving the intelligence behind talent management:
True Search
Global recruitment for board members, c-suite executives, VPs, directors, and other strategic talent. We focus on investment firms, their portfolio companies and public companies seeking transformative growth.
Thrive
Collaborative, real-time talent relationship management software and information services for search firms, in-house recruiters and VC/PE firms looking to make better hiring decisions.
Synthesis
A multi-layered approach to leadership assessment and development, which combines the evaluation methods of elite military units, executive coaching techniques and agile methodology principles.
AboveBoard
True co-founded AboveBoard, a diversity-focused startup bringing unparalleled solutions to the critical need to bring more women and executives of color to leadership roles. With AboveBoard's two-way platform, members get unique visibility to hundreds of opportunities while companies get access to qualified candidates.
True Equity
True Equity provides exposure to high-quality venture capital and growth equity investments. As a value-added talent partner, True Equity makes direct investments alongside premier investors. True Equity Fund I participates in Series A and B investments. True Equity Growth Fund II focuses on late stage venture and growth equity companies.
Vera
Vera is a family of investment funds that backs exceptional entrepreneurs and companies dedicated to changing our collective future through technology at the pre-seed, seed, early, and late stages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005587/en/
Contact information
Press:
Sarah Mikhailova
Vice President of Communications
sarah@trueplatform.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom